Free Trial
NYSE:NKGN

NKGen Biotech (NKGN) Stock Price, News & Analysis

NKGen Biotech logo
$0.27 0.00 (-0.76%)
As of 11:42 AM Eastern

About NKGen Biotech Stock (NYSE:NKGN)

Key Stats

Today's Range
$0.27
$0.31
50-Day Range
$0.10
$0.36
52-Week Range
$0.10
$1.75
Volume
61,130 shs
Average Volume
1.57 million shs
Market Capitalization
$12.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Receive NKGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NKGen Biotech and its competitors with MarketBeat's FREE daily newsletter.

NKGN Stock News Headlines

NKGen Biotech Chairman & CEO Paul Y. Song, M.D.
This document could hand you a shot at $915 every single weekend!
Something fascinating happens in the options market when most traders aren't paying attention… While everyone else collects standard daily premiums Monday through Friday... There's a special opportunity to target TRIPLE premiums just for holding positions over the weekend. Think about that... Most traders get one day's worth of premium for their trades. But by entering right before the weekend, when everything works out, you could collect THREE days worth - even though markets are closed for two of them. Thanks to a special discovery by a Wall Street legend who helped manage a $1.7 trillion firm – regular folks like you can now target extra cash from the markets on weekends… Just like he showed his small group of traders on December 20th with KO... A quick 2-minute setup Friday afternoon… Head out for the weekend... Monday morning? An extra $1,111 sitting in the account (with a $5k starting stake).
NKGen Biotech presents data from Phase 1/2a trial of troculeucel
See More Headlines

NKGN Stock Analysis - Frequently Asked Questions

NKGen Biotech's stock was trading at $0.6552 at the beginning of the year. Since then, NKGN stock has decreased by 58.3% and is now trading at $0.2729.
View the best growth stocks for 2025 here
.

NKGen Biotech's top institutional shareholders include University of Chicago (0.72%). Insiders that own company stock include Paul Y Song and James A Graf.
View institutional ownership trends
.

Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NKGen Biotech investors own include Meta Platforms (META), IonQ (IONQ), Eli Lilly and Company (LLY), NVIDIA (NVDA), Viking Therapeutics (VKTX), Adaptimmune Therapeutics (ADAP) and C3.ai (AI).

Company Calendar

Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:NKGN
Previous Symbol
NYSE:NKGN
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$82.94 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Price / Cash Flow
N/A
Book Value
($2.68) per share
Price / Book
-0.10

Miscellaneous

Free Float
40,291,000
Market Cap
$12.36 million
Optionable
Not Optionable
Beta
0.84
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NYSE:NKGN) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners